ATRS:NSD-Antares Pharma Inc (USD)

COMMON STOCK | Medical Instruments & Supplies | NSD

Last Closing Price

USD 3.34

Change

+0.08 (+2.45)%

Market Cap

USD 0.54B

Volume

0.46M

Avg Analyst Target

USD 5.83 (+74.65%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

Antares Pharma Inc (ATRS) Stock Analysis:
Based on the Antares Pharma Inc stock forecasts from 2 analysts, the average analyst target price for Antares Pharma Inc is USD 5.83 over the next 12 months. Antares Pharma Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Antares Pharma Inc is Slightly Bullish , which is based on 10 positive signals and 6 negative signals. At the last closing, Antares Pharma Inc’s stock price was USD 3.34. Antares Pharma Inc’s stock price has changed by +0.11 % over the past week, -0.46 % over the past month and -2.91 % over the last year.

About

Antares Pharma, Inc., a specialty pharmaceutical company, focuses primarily on the development and commercialization of pharmaceutical products and technologies that address unmet needs in targeted therapeutic areas. It develops, manufactures, and commercialize novel therapeutic ...Read More

Company Website : https://www.antarespharma.com

Address : 100 Princeton South, Ewing, NJ, United States, 08628

Employees : 185

Fiscal Year End : December

Currency: USD

Country : USA

Technical Indicators

Beta : 1.52

52 Week High : 5.07

Short Ratio : 4.08

52 Week Low : 3.11

Shorted Shares : 2,659,065

200 Day Moving Average : 3.96

Shorted Shares Previous Month : 4,038,442

50 Day Moving Average : 3.55

Shares Held By Insiders : 2.24%

Short Percentage : 2.00%

Shares Held by Institutions : 50.26%

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-12-07 )

Largest Industry Peers for Medical Instruments & Supplies

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
ISRG Intuitive Surgical Inc

+16.72 (+5.16%)

 USD114.90B 69.81 52.86
HOLX Hologic Inc

+1.73 (+2.32%)

 USD18.59B 10.32 7.19
MASI Masimo Corporation

+2.49 (+0.89%)

 USD15.29B 69.76 49.04
RGEN Repligen Corporation

+11.08 (+4.48%)

 USD14.53B 117.84 78.62
XRAY DENTSPLY SIRONA Inc

+1.12 (+2.17%)

 USD11.09B 27.09 13.69
NVCR NovoCure Limited

+6.64 (+7.97%)

 USD8.52B 1,480.87 3,956.59
ICUI ICU Medical Inc

+3.82 (+1.70%)

 USD4.69B 44.57 18.43
STAA STAAR Surgical Company

+4.19 (+4.58%)

 USD4.25B 195.05 121.74
MMSI Merit Medical Systems Inc

+1.02 (+1.56%)

 USD3.57B 85.57 25.39
ATRC AtriCure Inc

+3.49 (+5.16%)

 USD3.01B 68.07 49.04

ETFs Containing ATRS

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Medical Instruments & Supplies)		 Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -16.29% 40% F 30% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -16.29% 40% F 30% F
Trailing 12 Months  
Capital Gain -2.91% 43% F 37% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -2.91% 40% F 35% F
Trailing 5 Years  
Capital Gain 67.00% 42% F 64% D
Dividend Return N/A N/A N/A N/A N/A
Total Return 67.00% 42% F 62% D-
Average Annual (5 Year Horizon)  
Capital Gain 15.39% 33% F 60% D-
Dividend Return N/A N/A N/A N/A N/A
Total Return 15.39% 33% F 59% F
Risk Return Profile  
Volatility (Standard Deviation) 31.25% 80% B- 57% F
Risk Adjusted Return 49.25% 50% F 66% D
Market Capitalization 0.54B 45% F 56% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Medical Instruments & Supplies)		 Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 8.72 88% B+ 75% C
Price/Book Ratio 3.80 45% F 33% F
Price / Cash Flow Ratio 25.12 36% F 17% F
EV/EBITDA 16.98 71% C- 41% F
Management Effectiveness  
Return on Equity 63.08% 97% A+ 98% A+
Return on Invested Capital 47.00% 100% A+ 96% A
Return on Assets 8.81% 84% B 90% A-
Debt to Equity Ratio 20.71% 61% D- 58% F
Technical Ratios  
Short Ratio 4.08 39% F 35% F
Short Percent 1.60% 67% D+ 63% D
Beta 1.52 35% F 26% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date
New Post

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

Underpriced compared to earnings

The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters then its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.